Influence of Dosing Interval and Administration on the Bone Metabolism, Skeletal Effects, and Clinical Efficacy of Parathyroid Hormone in Treating Osteoporosis: A Narrative Review

• Published in: JBMR plus Vol. 1; no. 1; pp. 36 - 45
• Main Authors: Kim, Kyoung Min, Lee, Sae Young, Rhee, Yumie
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.08.2017; John Wiley and Sons Inc
• Subjects: Bone growth; Bone mineral density; Bone resorption; Bone turnover; Clinical medicine; Fractures; Gene expression; Kinases; Menopause; Metabolism; Osteogenesis; Osteoporosis; Parathyroid; Parathyroid hormone; Post-menopause; Proteins; Review; Reviews; Signal transduction; Women; TERIPARATIDE; PARATHYROID HORMONE; DOSING INTERVAL; FRACTURE REDUCTION; OSTEOPOROSIS

Recombinant human parathyroid hormone (PTH) is the key anabolic agent used for preventing fracture in postmenopausal women with osteoporosis. In bone metabolism, PTH signaling is mediated through a G protein-coupled receptor that affects various post-receptor signaling pathways. Results of preclinic...